NCAM1 and Merkel cell skin cancer: A conjugate that combines a CD56-targeting antibody to the cytotoxic drug, monomethyl auristatin E inhibits growth in mouse xenograft models of MCC.A Phase I clinical trial using a different (subsequently discontinued) CD56-targeting conjugate reported responses in a minority of patients with MCC.